Clinical Study
Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Table 1
Patient characteristics.
| | Parameter | pT3a (, 69.2%) | pT3b (, 30.8%) | All (, 100%) |
| | Median age (yr) (range) | 66.5 (49–78) | 65 (48–76) | 66 (48–78) | | Median PSA (ng/mL) (range) | 7.63 (0.68–39.89) | 11.6 (3.1–98.4) | 8.67 (0.68–98.4) | Mean biopsy Gleason (range)
Gleason ≤6
Gleason 7
Gleason ≥8 | 6.4 (6–9)
68.3%
26.0%
5.7% | 6.8 (5–10)
41.1%
41.1%
17.9% | 6.5 (5–10)
59.8%
30.7%
9.5% | Mean surgery Gleason (range)
Gleason ≤6
Gleason 7
Gleason ≥8 | 6.9 (6–9)
19.8%
71.4%
8.8% | 7.5 (6–9)
3.6%
58.2%
38.2% | 7.1 (6–9)
14.9%
67.4%
17.7% | | R (%) | 54.2% | 71.7% | 59.5% | | N+ (rate) | 2.8% (2/71) | 23.8% (10/42) | 10.6% (12/113) | | PSA relapse | 29.6% | 75.0% | 43.6% | | Deaths (rate) | 3.2% (4/126) | 23.2% (13/56) | 9.3% (17/182) | | Deaths from cancer (rate) | 0.8% (1/126) | 17.9% (10/56) | 6% (11/182) | | mts | 2.4% | 17.9% | 7.1% | | Median followup (mo) (range) | 56 (7–96) | 50.5 (6–94) | 54 (6–96) |
|
|
